Research Triangle Park, North Carolina, March 5, 2013 – Marken today announced that it has appointed two independent directors to its Board as a result of Marken’s recent restructuring completed on December 21, 2012. The appointment of Timothy C. Tyson and Michael O’Donnell is the next step in Marken’s strategy to focus on serving the global life sciences industry.
Tim Tyson is a veteran leader in the global pharmaceutical market place. He currently serves as Chairman of the Board of Aptuit LLC, a global pharmaceutical services company based in the US. He was CEO and President of Valeant Pharmaceuticals Inc. from 2003-2008. Prior to that, Mr. Tyson held various leadership roles including as President, Global Manufacturing & Supply at GlaxoSmithKline (GSK). During his 14 years at GSK, he led the Glaxo Dermatology and Cerenex Divisions, the US Marketing Division, and the US Sales Divisions where he launched 32 products, eight of which exceeded $1billion in global sales. Mr. Tyson is an engineering graduate of the US Military Academy at West Point, and holds a masters degree in public administration from Jackson State University. He has held key positions on the PhRMA Board and the International Society of Professional Engineers (ISPE).
Michael O’Donnell currently serves as Chairman of Verna, a company specializing in infectious control products, and as non-executive Director of Helical Bar plc. a property development firm. He has served as an independent Director on the Boards of seven companies since 2008 and also acted as a consultant to one of Marken’s clients. Prior to 2008, Mr. O’Donnell was a Managing Director of LGV Capital, a private equity firm, where he worked for more than a decade. He started his career at Morgan Grenfell where he worked for five years after graduating from University College, Dublin with a Bachelor of Commerce degree.
“We are delighted to welcome Tim and Michael to Marken’s Board of Directors,” said Wes Wheeler, Marken’s Chief Executive Officer. “These two independent Directors will certainly provide us with an appropriate balance of deep industry and financial experience. They also bring excellent contacts from the pharmaceutical industry and the UK financial markets, respectively, which will allow us to continue our expansion in the life sciences supply chain market.”